Introduction: Acromegaly is a rare endocrinopathy, potentially fatal by its metabolic, cardiovascular and neoplastic impact. The aim of this work is to study the cardiovascular impact of acromegaly and cardiovascular risk factors during acromegaly.
Materials: This is a retrospective, descriptive study of 43 acromegalic patients admitted to the Department of Endocrinology, Diabetology and Metabolic Diseases CHU IBN ROCHD, Casablanca from January 2005 to December 2018.
Results: The average age of our patients was 48 years (1373), with sex ratio H / F: 0.53. HBP was present in 37.2%, glycoregulatory abnormalities in 60% of cases, dyslipidemia in 41% and hyperuricemia in 5%. Cardiovascular examination revealed irregular rhythm in one patient and dyspnea stage II was noted in 32% of cases and stage III in 39%. Obesity was observed in 49% of cases. Cardiac ultrasound found hypertrophic cardiomyopathy in 7% of patients. The association of two risk factors was observed in 26.2%, three risk factors in 13.9% and four risk factors in 13.9%. The other patients a reduction in the number of antihypertensives and an improvement in their metabolic profile were also appreciated.
Discussion: Cardiac involvement is constant during acromegaly. HBP is more frequent and severe as the disease is older and the incidence of other cardiovascular risk factors is higher than the general population requiring multidisciplinary management to improve the cardiovascular prognosis.
18 - 21 May 2019
European Society of Endocrinology